Pathological response and survival outcomes after neoadjuvant chemotherapy with radical cystectomy in octogenarians for muscle-invasive bladder cancer: an observational database study

Background Neoadjuvant chemotherapy (NAC) with radical cystectomy (RC) is the preferred first-line treatment for localized muscle-invasive bladder cancer (MIBC).

In recent years, octogenarians have been undergoing RC uneventfully, but studies showed older adults receive NAC less often.

We studied the utilization and effect of RC with or without NAC in octogenarians and compared survival outcomes between responders and non-responders.

Methods In our retrospective study using the National Cancer Database (NCDB), we identified octogenarians with MIBC and urothelial histology who underwent RC with or without NAC between 2004 and 2018.

The NAC cohort included patients who underwent RC with NAC, and the non-NAC cohort included those with or without adjuvant chemotherapy.

The NAC cohort was subcategorized into responders and non-responders based on surgical pathology.

Patients with comorbidity index > 1 were not included, thereby excluding patients with possible renal impairment.

After propensity-matching, we compared the overall survival (OS) between NAC and non-NAC cohorts and responders and non-responders.

Results 33924 patients underwent RC, and 3056 octogenarians met our selection.

Among them, 396 received NAC, and 2660 did not receive NAC.

Among those who received NAC, 112(28.3%) experienced downstaging, and 223(56.4%) exhibited upstaging or no change ( p  < 0.001).

After propensity-matching, the median OS of the NAC and non-NAC cohorts were 51.6 months and 31.3 months, respectively (p<0.001).

Similarly, the median OS of responders and non-responders were 89.4 months and 26.5 months, respectively( p  < 0.0001).

Conclusion In our study, we observed that NAC with RC for MIBC may help to improve OS among healthy octogenarians.

Similarly, responders had better OS than non-responders.